- Home
- CSX vs REGN Comparison
CSX vs REGN Comparison
Compare CSX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSX
- REGN
- Stock Information
- Founded
- CSX 1978
- REGN 1988
- Country
- CSX United States
- REGN United States
- Employees
- CSX N/A
- REGN N/A
- Industry
- CSX Railroads
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- CSX Industrials
- REGN Health Care
- Exchange
- CSX Nasdaq
- REGN Nasdaq
- Market Cap
- CSX 60.6B
- REGN 63.4B
- IPO Year
- CSX N/A
- REGN 1991
- Fundamental
- Price
- CSX $33.60
- REGN $547.31
- Analyst Decision
- CSX Buy
- REGN Buy
- Analyst Count
- CSX 23
- REGN 22
- Target Price
- CSX $34.30
- REGN $839.91
- AVG Volume (30 Days)
- CSX 13.7M
- REGN 1.2M
- Earning Date
- CSX 07-23-2025
- REGN 08-01-2025
- Dividend Yield
- CSX 1.55%
- REGN 0.64%
- EPS Growth
- CSX N/A
- REGN 16.49
- EPS
- CSX 1.68
- REGN 39.43
- Revenue
- CSX $14,282,000,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- CSX N/A
- REGN N/A
- Revenue Next Year
- CSX $4.65
- REGN $6.78
- P/E Ratio
- CSX $19.98
- REGN $13.88
- Revenue Growth
- CSX N/A
- REGN 7.52
- 52 Week Low
- CSX $26.22
- REGN $476.49
- 52 Week High
- CSX $37.10
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- CSX 69.60
- REGN 57.41
- Support Level
- CSX $32.10
- REGN $514.79
- Resistance Level
- CSX $33.82
- REGN $531.21
- Average True Range (ATR)
- CSX 0.48
- REGN 13.62
- MACD
- CSX 0.04
- REGN 6.38
- Stochastic Oscillator
- CSX 88.89
- REGN 96.86
About CSX CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $14.5 billion in 2024. On its more than 21,000 miles of track, CSX hauls shipments of coal (16% of consolidated revenue), chemicals (17%), intermodal containers (16%), automotive cargo (7%), and a diverse mix of other bulk and industrial merchandise.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).